{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:38:06Z","timestamp":1792467486594,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-026-01440-y","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:53:04Z","timestamp":1773672784000},"page":"1513-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A comparison of the national European guidelines: RSV vaccination in older adults"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2433-4959","authenticated-orcid":false,"given":"Marie-Justine","family":"Desrumaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Flamaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1440_CR1","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1099\/jgv.0.000959","volume":"98","author":"B Rima","year":"2017","unstructured":"Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA et al (2017) ICTV virus taxonomy profile: pneumoviridae. J Gen Virol 98:2912\u20132913. https:\/\/doi.org\/10.1099\/jgv.0.000959","journal-title":"J Gen Virol"},{"key":"1440_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","volume":"38","author":"EE Walsh","year":"2017","unstructured":"Walsh EE (2017) Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med 38:29\u201336. https:\/\/doi.org\/10.1016\/j.ccm.2016.11.010","journal-title":"Clin Chest Med"},{"key":"1440_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2216358","volume":"388","author":"BS Graham","year":"2023","unstructured":"Graham BS (2023) The journey to RSV vaccines\u2014heralding an era of structure-based design. N Engl J Med 388:579\u2013581. https:\/\/doi.org\/10.1056\/NEJMp2216358","journal-title":"N Engl J Med"},{"key":"1440_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00002512-200522070-00004","volume":"22","author":"AR Falsey","year":"2005","unstructured":"Falsey AR, Walsh EE (2005) Respiratory Syncytial Virus infection in elderly adults. Drugs Aging 22:577\u2013587. https:\/\/doi.org\/10.2165\/00002512-200522070-00004","journal-title":"Drugs Aging"},{"key":"1440_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QCO.0000000000001000","volume":"37","author":"S Kenmoe","year":"2024","unstructured":"Kenmoe S, Nair H (2024) The disease burden of Respiratory Syncytial Virus in older adults. Curr Opin Infect Dis 37:129\u2013136. https:\/\/doi.org\/10.1097\/QCO.0000000000001000","journal-title":"Curr Opin Infect Dis"},{"key":"1440_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","volume":"32","author":"AR Branche","year":"2015","unstructured":"Branche AR, Falsey AR (2015) Respiratory Syncytial Virus infection in older adults: an under-recognized problem. Drugs Aging 32:261\u2013269. https:\/\/doi.org\/10.1007\/s40266-015-0258-9","journal-title":"Drugs Aging"},{"key":"1440_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/infdis\/jiaa331","volume":"223","author":"ML Jackson","year":"2021","unstructured":"Jackson ML, Scott E, Kuypers J, Nalla AK, Roychoudury P, Chu HY (2021) Epidemiology of Respiratory Syncytial Virus across five influenza seasons among adults and children one year of age and older\u2014Washington State, 2011\/2012\u20132015\/2016. J Infect Dis 223:147\u2013156. https:\/\/doi.org\/10.1093\/infdis\/jiaa331","journal-title":"J Infect Dis"},{"key":"1440_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0105-2022","volume":"31","author":"JS Nguyen-Van-Tam","year":"2022","unstructured":"Nguyen-Van-Tam JS, O\u2019Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R et al (2022) Burden of Respiratory Syncytial Virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev 31:220105. https:\/\/doi.org\/10.1183\/16000617.0105-2022","journal-title":"Eur Respir Rev"},{"key":"1440_CR9","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X et al (2020) Global disease burden estimates of Respiratory Syncytial Virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 222:S577\u2013S583. https:\/\/doi.org\/10.1093\/infdis\/jiz059","journal-title":"J Infect Dis"},{"key":"1440_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031","author":"M Savic","year":"2023","unstructured":"Savic M, Penders Y, Shi T, Branche A, Pir\u00e7on JY (2023) Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. https:\/\/doi.org\/10.1111\/irv.13031","journal-title":"Influenza Other Respir Viruses"},{"key":"1440_CR11","unstructured":"CHMP (n.d.) Arexvy, INN-Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)"},{"key":"1440_CR12","unstructured":"CHMP (n.d.) Abrysvo, INN-respiratory syncytial virus vaccine (bivalent, recombinant)"},{"key":"1440_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M et al (2023) Efficacy and safety of a bivalent RSV Prefusion F vaccine in older adults. N Engl J Med 388:1465\u20131477. https:\/\/doi.org\/10.1056\/NEJMoa2213836","journal-title":"N Engl J Med"},{"key":"1440_CR14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMc2311560","volume":"391","author":"EE Walsh","year":"2024","unstructured":"Walsh EE, P\u00e9rez Marc G, Falsey AR, Jiang Q, Eiras D, Patton M et al (2024) RENOIR trial\u2014RSVpreF vaccine efficacy over two seasons. N Engl J Med 391:1459\u20131460. https:\/\/doi.org\/10.1056\/NEJMc2311560","journal-title":"N Engl J Med"},{"key":"1440_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf061","author":"EE Walsh","year":"2025","unstructured":"Walsh EE, Eiras D, Woodside J, Jiang Q, Patton M, Marc GP et al (2025) Efficacy, immunogenicity, and safety of the bivalent Respiratory Syncytial Virus (RSV) prefusion F vaccine in older adults over 2 RSV seasons. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf061","journal-title":"Clin Infect Dis"},{"key":"1440_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509810","author":"MCH Lassen","year":"2025","unstructured":"Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D et al (2025) RSV prefusion F vaccine for prevention of hospitalization in older adults. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2509810","journal-title":"N Engl J Med"},{"key":"1440_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/nejmoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee D-G, Leroux-Roels I, Martinon-Torres F et al (2023) Respiratory Syncytial Virus prefusion F protein vaccine in older adults. N Engl J Med 388:595\u2013608. https:\/\/doi.org\/10.1056\/nejmoa2209604","journal-title":"N Engl J Med"},{"key":"1440_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"MG Ison","year":"2025","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG et al (2025) Efficacy, safety, and immunogenicity of the AS01E-adjuvanted Respiratory Syncytial Virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three Respiratory Syncytial Virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med 13:517\u2013529. https:\/\/doi.org\/10.1016\/S2213-2600(25)00048-7","journal-title":"Lancet Respir Med"},{"key":"1440_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","volume":"404","author":"AB Payne","year":"2024","unstructured":"Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP et al (2024) Respiratory Syncytial Virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October 2023, to March, 2024: a test-negative design analysis. Lancet 404:1547\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(24)01738-0","journal-title":"Lancet"},{"key":"1440_CR20","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/nejmoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K et al (2023) Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med 389:2233\u20132244. https:\/\/doi.org\/10.1056\/nejmoa2307079","journal-title":"N Engl J Med"},{"key":"1440_CR21","unstructured":"EMA. mResvia n.d. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia. Accessed 2 Nov 2025"},{"key":"1440_CR22","unstructured":"Vaccine Scheduler | ECDC n.d. https:\/\/vaccine-schedule.ecdc.europa.eu\/. Accessed 1 May 2024"},{"key":"1440_CR23","unstructured":"Bundesministerium Soziales G Pflege und Konsumentenschutz (n.d.) Impfplan Osterreich 2024\/2025 (Austria, version December 2025)"},{"key":"1440_CR24","unstructured":"Superior Health Council (n.d.) Vaccination against RSV for older adults (Belgium, version of December 2024)"},{"key":"1440_CR25","unstructured":"Ministry of health Cyprus (2024) National Vaccination Program for Adults and Risk groups (Cyprus, version 2024)"},{"key":"1440_CR26","unstructured":"Minist\u00e8re charg\u00e9 de la sant\u00e9 et de l\u2019acc\u00e8s aux soins (n.d.) Calendrier des vaccinations et recommandations vaccinales 2025 (France, version April 2024)"},{"key":"1440_CR27","unstructured":"Robert Koch Institute (n.d.) Answers to frequently asked questions about vaccination against RSV (Germany, Version May 2025)"},{"key":"1440_CR28","unstructured":"Hellenic Republic Ministry of Health General Directorate of Public Health and Quality of Life D of PH and EH Section A (n.d.) National Adult Immunization Program 2025 (Greece, version Mar 2025)"},{"key":"1440_CR29","unstructured":"National Immunisation Advisory Committee (n.d.) Recommendations for passive immunisation and vaccination against respiratory syncytial virus in children and older adults (Ireland, version October 2023)"},{"key":"1440_CR30","unstructured":"Conseil Sup\u00e9rieur des Maladies Infectieuses (2024) Avis du CSMI sur la vaccination contra le RSV chez l\u2019adulte (Luxembourg, version December 2024)"},{"key":"1440_CR31","unstructured":"National Administration Principality of Liechtenstein (n.d.) Vaccination\u2014protection against infections (Liechtenstein, version June 2025)"},{"key":"1440_CR32","unstructured":"Infovac (n.d.) Empfehlungen zur Impfung und Immunisierung gegen das Respiratorische Synzytial-Virus (RSV). (Switzerland, version July 2025)"},{"key":"1440_CR33","unstructured":"Folkehelseinstituttet (n.d.) RSV-vaksine\u2014h\u00e5ndbok for helsepersonell (Norway, version April 2025)"},{"key":"1440_CR34","unstructured":"Dzennik Urz\u0119dowy ministra zdrowia (n.d.) Komunikat Glownego inspektora sanitarnego w sprawie Programu Szczepie\u0144 Ochronnych na rok 2025 (Poland, version October 2024)"},{"key":"1440_CR35","unstructured":"Cepljenje (n.d.) RSV (Slovenia, accessed on 27 July 2025)"},{"key":"1440_CR36","unstructured":"Folkh\u00e4lsomyndigheten (n.d.) Allvarlig RS-virusinfektion bland barn och vuxna iSverge (Sweden, version May 2024)"},{"key":"1440_CR37","unstructured":"Department of Health and Social Care (2025) Respiratory syncytial virus (RSV) immunisation programme for adults aged 80 years and older: JVCI advice (United Kingdom, version July 2025)"},{"key":"1440_CR38","unstructured":"United Nations n.d. https:\/\/esa.un.org\/MigFlows\/Definition%20of%20regions.pdf. Accessed 1 May 2024"},{"key":"1440_CR39","unstructured":"Zorginstituut Nederland (2025) Verbindende notitie van Zorginstituut Nederland en Gezondheidsraad bij advies over RSV-vaccinatie voor ouderen (The Netherlands, version April 2025)"},{"key":"1440_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s41999-024-01066-y","volume":"15","author":"AC Moreira","year":"2024","unstructured":"Moreira AC, Ribeiro AB, Oliveira I, S\u00e1 M, Lameir\u00e3o C, Marques P (2024) Efficacy of anti-RSV vaccination in preventing Respiratory Syncytial Virus disease and severe illness in older adults: a systematic review of randomized controlled trials. Eur Geriatr Med 15:1215\u20131229. https:\/\/doi.org\/10.1007\/s41999-024-01066-y","journal-title":"Eur Geriatr Med"},{"key":"1440_CR41","doi-asserted-by":"publisher","unstructured":"Surie D. Effectiveness of adult respiratory syncytial virus (RSV) vaccines, 2023\u20132024 National Center for Immunization and Respiratory Diseases 2024. https:\/\/doi.org\/10.1001\/jama.1996.03530290060038","DOI":"10.1001\/jama.1996.03530290060038"},{"key":"1440_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1473-3099(24)00796-5","volume":"25","author":"KL Bajema","year":"2025","unstructured":"Bajema KL, Yan L, Li Y, Argraves S, Rajeevan N, Fox A et al (2025) Respiratory Syncytial Virus vaccine effectiveness among US veterans, September 2023 to March, 2024: a target trial emulation study. Lancet Infect Dis 25:625\u2013633. https:\/\/doi.org\/10.1016\/S1473-3099(24)00796-5","journal-title":"Lancet Infect Dis"},{"key":"1440_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8322","author":"SE Fry","year":"2025","unstructured":"Fry SE, Terebuh P, Kaelber DC, Xu R, Davis PB (2025) Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8322","journal-title":"JAMA Netw Open"},{"key":"1440_CR44","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","volume":"73","author":"A Britton","year":"2024","unstructured":"Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M et al (2024) Use of respiratory syncytial virus vaccines in adults aged \u226560 years: Updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024. MMWR Morb Mortal Wkly Rep 73:696\u2013702. https:\/\/doi.org\/10.15585\/mmwr.mm7332e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1440_CR45","unstructured":"Melgar M, Britton A (2024) RSV Vaccination in Adults: Work Group Interpretations National Center for Immunization and Respiratory Diseases"},{"key":"1440_CR46","unstructured":"Lloyd P (n.d.) Evaluation of Guillain-Barr\u00e9 Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Respiratory Syncytial Virus (RSV) Vaccine, Adults"},{"key":"1440_CR47","unstructured":"U.S. Food and Drug (2025) FDA requires Guillain-Barr\u00e9 syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy"},{"key":"1440_CR48","unstructured":"Crawford R, Bailey S, Cornelissen T (n.d.) Cost-effectiveness of respiratory syncytial virus vaccines for adults"},{"key":"1440_CR49","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/cid\/ciad658","volume":"78","author":"SM Moghadas","year":"2024","unstructured":"Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC et al (2024) Cost-effectiveness of prefusion F protein-based vaccines against Respiratory Syncytial Virus disease for older adults in the United States. Clin Infect Dis 78:1328\u20131335. https:\/\/doi.org\/10.1093\/cid\/ciad658","journal-title":"Clin Infect Dis"},{"key":"1440_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.50832","volume":"7","author":"SY Tartof","year":"2024","unstructured":"Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B et al (2024) Estimated vaccine effectiveness for Respiratory Syncytial Virus-related lower respiratory tract disease. JAMA Netw Open 7:e2450832. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.50832","journal-title":"JAMA Netw Open"},{"key":"1440_CR51","unstructured":"Hutton DW (n.d.) Economic analysis of RSV vaccination in adults 50 years and older"},{"key":"1440_CR52","unstructured":"Ortega-Sanchez I (2023) Economics of vaccinating U.S. Adults \u226560 years-old against Respiratory Syncytial Virus National Center for Immunization & Respiratory Diseases"},{"key":"1440_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126294","author":"DW Hutton","year":"2024","unstructured":"Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ et al (2024) Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126294","journal-title":"Vaccine"},{"key":"1440_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","volume":"24","author":"A Averin","year":"2025","unstructured":"Averin A, Huebbe B, Atwood M, Bayer LJ, Lade C, von Eiff C et al (2025) Cost-effectiveness of bivalent Respiratory Syncytial Virus prefusion F vaccine for prevention of Respiratory Syncytial Virus among older adults in Germany. Expert Rev Vaccines 24:1\u201310. https:\/\/doi.org\/10.1080\/14760584.2024.2436183","journal-title":"Expert Rev Vaccines"},{"key":"1440_CR55","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","volume":"78","author":"MG Ison","year":"2024","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG et al (2024) Efficacy and safety of Respiratory Syncytial Virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 78:1732\u20131744. https:\/\/doi.org\/10.1093\/cid\/ciae010","journal-title":"Clin Infect Dis"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01440-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-026-01440-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01440-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:14:03Z","timestamp":1782465243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-026-01440-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1007\/s41999-026-01440-y","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, no ethical approval were required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, no informed consent were required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}